Dr Faridani is interested in developing single-cell transcriptomic technologies to characterise circulating tumour cells (CTCs). CTCs are diverse cells in the form of single cells or cell clusters that are released by solid tumours into the circulation (blood circulation and lymphatic system). CTCs can be used as a liquid biopsy to obtain information from tumours in a minimally invasive way. He aims to investigate whether CTC can potentially serve as a predictive/prognostic biomarker in solid cancers.
Dr Faridani completed his PhD at the Karolinska Institute in Sweden where he studied the biology of natural antisense RNAs. Then, he moved to the lab of professor Rickard Sandberg at Ludwig Institute for Cancer Research as a postdoc to develop single-cell sequencing technologies. Later, he worked as a senior scientist at the Karolinska/AstraZeneca Integrated Cardiometabolic Center. Here, at UNSW, Dr Faridani a group leader at the Lowy Cancer Research Centre at the Adult Cancer Program. He is also a group leader at the Garvan Institute of Medical Research.
I have received the 2019 Pathfinders Award for the work of developing a device that enriches CTCs from the blood of cancer patients.